ISHLT2024: Industry Symposia - Wednesday

Abbott

Building NEW Bridges: Innovating Beyond Conventional LVAD Practices

A provocative discussion on how challenging and moving beyond traditional LVAD practices can light the way for transforming current and future advanced heart failure care.

Program

Construction Ahead: Building the Future of HF Care

Melana Yuzefpolskaya, MD, New York-Presbyterian/Columbia University Medical Center, New York City, NY USA

Engineering Advancements in HF Care Through Innovative Practice

Thomas Schlöglhofer, Msc, Medical University Of Vienna, Vienna, Austria

Beyond the Blueprint: Surgical Innovation in LVAD Therapy

Ivan Netuka, MD, PhD, Institute For Clinical And Experimental Medicine, Prague, Czech Republic

If You Build It, They Will Come: New Multicenter Cardiac Recovery Data Paving the Way Forward

Stavros Drakos, MD, PhD, FACC, University Of Utah Health, Salt Lake City, UT USA

Abiomed

Reshaping Heart Recovery: Impella's Role in Acute Decompensated Heart Failure Patient Management

Primary Core Therapy: MCS | Primary Practice Area: Cardiothoracic Surgery

Discover diverse global perspectives as healthcare professionals share their experiences in utilizing the Impella portfolio to enhance myocardial recovery. Gain insights from real-world ICU scenarios, learning how Key Opinion Leaders optimize patient support using Impella during critical treatment phases.

Speakers

Koichiro Kingugawa, MD, University of Toyama, Toyama, Japan
Bart Meyns, MD, UZ Leuven, Lueven, Belgium
Federico Pappalardo, MD, Azienda Ospedaliero-Universitaria di Alessandria, Alessandria, Italy
Jane Wilcox, MD, MSc, Northwestern Feinberg School of Medicine, Chicago, IL USA

CareDx

Innovations in Post-Lung Transplant Care: Integrating Molecular Diagnostics and Multimodal Remote Monitoring for Enhanced Clinical Decision-Making

Primary Core Therapy: Lung | Primary Practice Area: Pulmonology

The symposium will be an interactive case discussion of the clinical utility for decision making of (1) donor-derived cell-free DNA for bilateral lung transplant recipient in a surveillance manner and (2) remote home monitoring. The moderator will take the audience through two separate cases in which surveillance AlloSure lung testing is done on a monthly basis during the first year post-transplant and the panelists will describe their preferred course of action as it relates to performance of bronchoscopies, biopsies, repeat testing or adjustment in immunosuppression. Next, the moderator will describe a use case for remote home monitoring of a transplant patient, and the audience will describe their centers’ practice with this and their preferred course of action for this patient.

Speakers

Alice Gray, MD, University of Colorado, Denver, CO USA
Jake Natalini, MD, MSc, NYU Langone Transplant Institute, New York, NY USA
Kapilkumar Patel, MD, University of South Florida Morsani College of Medicine, Tampa, FL USA

Medtronic

Sustaining Good Outcomes in HVAD Patients for the Long-Haul: A Discussion on Center-Derived Protocols

Primary Core Therapy: MCS | Primary Practice Area: Cardiology

Clinicians managing HVAD patients continue to benefit from sharing best practices for optimal patient care. This symposium will focus on highlighting centers who have developed protocols for the ongoing management of HVAD patients and how those protocols have resulted in consistent outcomes.

Moderator

Diyar Saeed, MD, PhD, Helios Hospital Krefeld, Krefeld, Germany

Program

Utilization of Logfiles & Waveforms for Optimal Outcomes

Liviu Klein, MD, MS, University of California San Francisco, San Francisco, CA USA

Standardizing the HVAD Controller Exchange

Laura Coyle, MSN, ACNP-BC, Advocate Christ Medical Center, Oak Lawn, IL USA

Importance of Fundamentals: Blood Pressure & Anticoagulation Management

Laurens Tops, MD, Leiden University Medical Center, Leiden, Netherlands

Unique Approaches to HVAD Driveline Infection Management

Lutz Hilker, MD, Klinikum Karlsburg, Karlsburg, Germany

Natera

It’s Complicated: Is There Utility of dd-cfDNA Surveillance for Improved Management of AMR Post-Cardiac Transplantation?

Primary Core Therapy: Heart | Primary Practice Area: Cardiology

This lunch symposia will include a compelling review of the current AMR guidelines and clinical management challenges. Additionally, the panel experts will also integrate a basic science review of dd cfDNA and its utility as a post AMR treatment surveillance strategy.

Moderator

Michael Olymbios, MD, Natera, Austin, TX USA

Program

Current Guidelines and Controversies for the Clinical Management of AMR

Shelley Hall, MD, Baylor University Medical Center, Dallas, TX USA

Clinical Case Studies Highlighting Utility of dd-cfDNA Surveillance for Improved AMR Management

Patrick Campbell, MD, Baptist Health Medical Center, Little Rock, AR USA

Overview of Donor Derived Cell Free DNA Technology

Celeste Williams, MD, Henry Ford Health, Detroit, MI USA

XVIVO

What Determines a Good Lung From a Bad? Unlock the Power of Confidence

Primary Core Therapy: Lung | Primary Practice Area: Cardiothoracic Surgery

Lung transplantation is a complex procedure with several important steps that seamlessly need to come together to optimize outcome. It all starts with the procurement of lungs, where XVIVO’s organ recovery service can provide peace of mind for transplant centers. Once recovered, lungs are flushed with and then stored in PERFADEX® Plus. If transplanting extended criteria or DCD lungs that have undergone NRP, lung assessment with EVLP becomes an essential factor. Whether using just static cold storage or combining it with EVLP, new data indicates that an extra flush with PERFADEX® Plus before transplantation may improve outcomes.

Moderators

Marie Budev, DO, MPH, FCCP, Cleveland Clinic, Cleveland, OH USA
Marius Berman, MD, FRCS (CTh), Royal Papworth Hospital, Cambridge, United Kingdom

Program

Welcome

Christoffer Rosenblad, MSc, BSc, XVIVO, Mölndal, Sweden

DCD Lungs: Systematic Use of NRP and EVLP - The French Paradox!

Edouard Sage, MD, PhD, Hôpital Foch, Paris, France
Tips and tricks regarding the French national program of controlled DCD lung donors using systematically abdominal NRP and EVLP. The different NRP protocols and the interest of EVLP in this type of donor will be discussed.

Lung Transplantation: Flushing Matters

Niels van der Kaaij, MD, PhD, Erasmus Medical Center, Rotterdam, Netherlands
The outcome after lung transplantation might be impaired by development of primary graft dysfunction (PGD) and chronic lung allograft dysfunction (CLAD) and these are linked with regards to pathophysiology. Flushing of the pulmonary vasculature enables preservation of the endothelium, removal of pulmonary emboli and inflammatory cells and cytokines. In this research we focus on the potential beneficial effect of performing an additional retrograde flush shortly before implantation of the lung regarding incidence of PGD, severity of PGD, survival and time to extubation. Also we report on the outcomes of Hypothermic Oxygenated Perfusion (HOPE) for standard donor lungs (logistical indication, called Park & Preserve) in a cohort of 14 transplant patients as compared to a historical control group.

Peace of Mind, Delivered. Benefits of a Third-Party Organ Recovery Service

David Hormuth, MD, MBA, XVIVO Recovery Services, Philadelphia, PA USA